LMAT
Lemaitre Vascular·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LMAT
Lemaitre Vascular, Inc.
A provider of devices, implants and services for the treatment of peripheral vascular disease
Healthcare Equipment and Supplies
11/28/1983
10/19/2006
NASDAQ Stock Exchange
651
12-31
Common stock
63 Second Avenue
, Burlington
, Massachusetts 01803
--
Lemaitre Vascular, Inc., is a global supplier of medical devices and implanted devices for the treatment of peripheral vascular disease. The company was established on November 28, 1983. The company develops, manufactures and sells therapeutic instruments that meet the needs of vascular surgery. The Company's various peripheral vascular devices include branded products for external arteries and veins outside the heart (also known as vascular surgery), including the expandable LeMaitre heart valve knife, Pruitt F3 carotid artery shunt, and VascuTape opaque tape.
Historically, the Company has been a leading supplier of vascular surgical products for niche markets with lower or limited competition. Recently, the company hopes to use its market leadership in niche markets to sell integrated ancillary products to larger and more competitive markets. In addition, the company's vascular surgery product customers are gradually involving minimally invasive internal vascular therapy, which provides a good opportunity for the company to sell new products to address new needs.
Earnings Call
Q1/2025
Estimate EPS0.5
Actual EPS0.48
Estimate Revenue57.61M
Actual Revenue59.90M
LeMaitre Vascular's Q1 2025: Unpacking Contradictions in Sales Expansion, Margins, and Market Strategy
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.57
Actual EPS0.6
Estimate Revenue62.52M
Actual Revenue64.20M
LeMaitre Vascular's Q2 2025 Earnings Call: Unpacking Key Contradictions in Sales Growth, Pricing Strategies, and Market Opportunities
Aug 06,2025 12:15
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LMAT has released its 2025 Q3 earnings. EPS was reported at 0.62, versus the expected 0.56, beating expectations. The chart below visualizes how LMAT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LMAT has released its 2025 Q3 earnings report, with revenue of 61.05M, reflecting a YoY change of 11.36%, and net profit of 17.36M, showing a YoY change of 55.84%. The Sankey diagram below clearly presents LMAT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
